GlassScriptPhysician profile
Afton Cobb
NPI 1942662788
$1,264.83
in general payments reported to CMS, 2019-2025
12 companies · $465 in 2025
The $465 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $57.77 · 2022: $69.91 · 2023: $484 · 2024: $188 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,137.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $374.56 | 2022-2025 | |
| Abbvie INC. | $276.99 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $216.06 | 2023-2025 | Dupixent, Libtayo |
| Revance Therapeutics, INC. | $94.37 | 2025 | Daxi |
| Sun Pharmaceutical Industries INC. | $82.79 | 2025 | |
| Allergan, INC. | $60.02 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.37 | 2023 | Spevigo |
| Novartis Pharmaceuticals Corporation | $40.79 | 2025 | |
| Galderma Laboratories, L.P. | $18.23 | 2021 | |
| Lilly USA, LLC | $17.04 | 2023 | Olumiant, Taltz |
| Ucb, INC. | $13.59 | 2023 | Cimzia |
| Incyte Corporation | $12.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Afton Cobb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.